Raquel de Melo Alves Paiva

Raquel de Melo Alves Paiva

Auto-generated profile, based on publicly available information

Raquel de Melo Alves Paiva

Department of Hemotherapy and Cell Therapy, Einstein Hospital Israelita, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2022 in Blood
Verified
Journal Article
Open access
PDF file
FGFernanda Gutierrez-Rodrigues
Fernanda Gutierrez-Rodrigues
EMEric Munger
Eric Munger
XMXiaoyang Ma
Xiaoyang Ma
EGEmma M. Groarke
Emma M. Groarke
YTYoubao Tang
Youbao Tang
NYNeal S. Young
Neal S. Young
The choice to postpone treatment while awaiting genetic testing can result in significant delay in definitive therapies in severely pancytopenic patients. Conversely, inherited bone marrow failure (BMF) misdiagnosis can expose patients to ineffectual and expensive therapies, toxic transplant conditioning regimens, and inappropriate use of an affected family member as a stem cell donor. To predict the likelihood of patients having acquired or inherited BMF, we developed a two-step data-driven machine-learning model using 25 clinical and laboratory variables typically recorded at the initial clinical encounter. For model's development, patients were labeled as having acquired or inherited BMF depending on their genomic data. Datasets were unbiasedly clustered and an ensemble model was trained with cases from the largest cluster of the training cohort (n=359) and validated with an independent cohort (n=127). Cluster A, the largest group, was mostly immune or inherited aplastic anemia, whereas Cluster B was composed of underrepresented BMF phenotypes, and not included in the next step of data modeling due to small sample size. The ensemble model Cluster A-specific was accurate (89%) to predict BMF etiology, correctly predicting inherited and likely immune BMF in 79% and 92% of cases, respectively. Our model represents a practical guide for BMF diagnosis and highlights the importance of clinical and laboratory variables in the initial evaluation, particularly telomere length. Our tool can be potentially used by general hematologists and health care providers not specialized in BMF, and in under-resourced centers, to prioritize patients for genetic testing or for expeditious treatment.

13 November 2024 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
JAJúlia Teixeira Cottas de Azevedo
Júlia Teixeira Cottas de Azevedo
JGJuliana Aparecida Preto de Godoy
Juliana Aparecida Preto de Godoy
CSCláudia de Souza
Cláudia de Souza
MSMicheli Severo Sielski
Micheli Severo Sielski
LCLarissa Leggieri Coa
Larissa Leggieri Coa
RPRaquel de Melo Alves Paiva
Raquel de Melo Alves Paiva
Natural Killer cells are immune leukocytes required for responses against tumor cells and virus-infected cells. In the last decade, natural killer cells have emerged as promising tools in cancer therapy, and clinical studies on patients treated with natural killer cells have revealed increased rates of disease-free survival. In this article, we review results from the major clinical trials that have used natural killer cells for cancer treatment, including their global distribution. We also discuss the major mechanisms of natural

19 August 2022 in Stem Cells International
Verified
Journal Article
Open access
PDF file
MMMaria Susana Joya Marodin
Maria Susana Joya Marodin
JGJuliana Aparecida Preto de Godoy
Juliana Aparecida Preto de Godoy
RARaquel M. Alves-Paiva
Raquel M. Alves-Paiva
KAKelen Alvarez
Kelen Alvarez
TMThiago Giove Mitsugi
Thiago Giove Mitsugi
OOOswaldo Keith Okamoto
Oswaldo Keith Okamoto
Cytogenetic aberrations may emerge in human mesenchymal stromal cells (MSC) during ex vivo expansion for cell therapy. We have detected clonal trisomy 5 in two distinct autologous MSC products expanded from bone marrow which, based on the current quality control criteria, could not be released for clinical use. Although a safety concern, it is still unclear to what extent recurrent aneuploidies detected in MSC products may affect the threshold for neoplastic transformation or the medicinal properties of these cells. We have carried out an exploratory preclinical study to evaluate these MSC products with clonal trisomy 5, regarding their oncogenic and immunomodulatory potential. Cell population growth in vitro was reduced in MSC cultures with clonal trisomy 5 compared with the population growth of their euploid MSC counterparts, based on a lower cumulative population doubling level, reduced cell proliferation index, and increased senescence-associated beta-galactosidase activity. Subcutaneous injection of clinically relevant amount of MSC population, either with or without clonal trisomy 5, did not generate tumors in immunodeficient mice within a follow-up period of six months. Most importantly, MSC population with clonal trisomy 5 kept immunomodulatory properties upon interferon gamma (IFNγ) licensing, displaying overexpression of IDO, CXCL9, CXCL10, and CXCL11, in a similar fashion than that of IFNγ-licensed euploid MSC. Our findings suggest that bone marrow MSC products with clonal trisomy 5 may retain their therapeutic potential, based on poor tumor initiating capability and preserved immunomodulatory potency. This preclinical evidence may further support the definition of release criteria of autologous MSC products for cell therapy under critical clinical scenarios. This trial is registered with Clinical Study registration number: RBR-29x2pr.

8 July 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
CWCaroline Mitiká Watanabe
Caroline Mitiká Watanabe
CSCaroline Ishihama Suzuki
Caroline Ishihama Suzuki
ASAlessandro Marins dos Santos
Alessandro Marins dos Santos
TAThiago Pinheiro Arrais Aloia
Thiago Pinheiro Arrais Aloia
GLGrace Lee
Grace Lee
NHNelson Hamerschlak
Nelson Hamerschlak
Natural Killer (NK) cells play a crucial role in the immune system's response against cancer. However, the challenge of obtaining the required quantity of NK cells for effective therapeutic response necessitates the development of strategies for their ex vivo expansion. This study aimed to develop a novel feeder cell line, K562.Clone1, capable of promoting the ex vivo expansion of NK cells while preserving their cytotoxic potential. The K562 leukemic cell line was transduced with mbIL-21 and 4-1BBL proteins to generate K562.Clone1 cells. NK cells were then co-cultured with these feeder cells, and their expansion rate was monitored over 14 days. The cytotoxic potential of the expanded NK cells was evaluated against acute myeloid leukemia blasts and tumor cell lines of leukemia and glial origin. Statistical analysis was performed to determine the significance of the results. The K562.Clone1 co-cultured with peripheral NK showed a significant increase in cell count, with an approximately 94-fold expansion over 14 days. Expanded NK cells demonstrated cytotoxicity against the tested tumor cell lines, indicating the preservation of their cytotoxic characteristics. Additionally, the CD56, CD16, inhibitory KIRs, and activation receptors were conserved and present in a well-balanced manner. The study successfully developed a feeder cell line, K562.Clone1, that effectively promotes the expansion of NK cells ex vivo while maintaining their cytotoxic potential. This development could significantly contribute to the advancement of NK cell therapy, especially in Brazil.

5 February 2026 in Cytotherapy
Verified
Journal Article
Closed access
RARaquel de Melo Alves-Paiva
Raquel de Melo Alves-Paiva
LCLarissa L. Coa
Larissa L. Coa
JAJulia T. Azevedo
Julia T. Azevedo
JSJamile Ramos da Silva
Jamile Ramos da Silva
JGJuliana A. P de Godoy
Juliana A. P de Godoy
LKLucila N. Kerbauy
Lucila N. Kerbauy

8 January 2026 in JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Verified
Journal Article
Open access
LZLarissa Cardoso Zanetti
Larissa Cardoso Zanetti
RPRaquel de Melo Alves Paiva
Raquel de Melo Alves Paiva
LKLucila Nassif Kerbauy
Lucila Nassif Kerbauy
Chimeric antigen receptor (CAR) technology has transformed adoptive cell therapy, particularly through the success of CAR-T cells in hematologic malignancies. However, challenges such as toxicity, complex manufacturing, and high costs have encouraged the exploration of alternative immune cell platforms. Natural killer (NK) cells represent a promising approach due to their intrinsic cytotoxic activity, major histocompatibility complex-independent tumor recognition, and lower risk of severe immune-related toxicities. CAR-NK cells combine CAR-mediated antigen targeting with the natural antitumor functions of NK cells, supporting the development of safer and potentially “off-the-shelf” cellular therapies. This chapter reviews the biological rationale of CAR-NK cells, current gene engineering strategies, and the evolving clinical landscape, highlighting their potential in hematologic malignancies, solid tumors, and autoimmune diseases.